OS Therapies

OS Therapies CEO Paul Romness will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025, to update on OST-HER2 trial data. Anticipating FDA approval in 2025, the company could earn a $150M Priority Review Voucher, funding further development for HER2-positive cancers.

FINN Partners named global agency for Fiserv, focusing on brand and PR under "Fiserv Moves More than Money." B2i Digital adds OS Therapies, enhancing investor outreach. Percepture collaborates with Scope Technologies on quantum security initiatives.

OS Therapies partners with B2i Digital to boost investor awareness of its cancer immunotherapy research, focusing on OST-HER2 in Phase 2b trials for osteosarcoma, with clinical data updates expected at JP Morgan Healthcare Conference 2025.

OS Therapies announced a $6 million private placement, selling 1.5 million units at $4.00 each. Each unit includes one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock. The placement, expected to close around December 27, 2024, will fund operations into 2026, supporting clinical and regulatory milestones for OST-HER2, the company's lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. Phase 2b data for OST-HER2 will be announced during the JP Morgan Healthcare Conference in January 2025.

OS Therapies, Inc. reported Q3 2024 financial results and completed Phase 2b trial of OST-HER2 in osteosarcoma, with topline data expected in December 2024.

OS Therapies reported Q3 2024 financial results, including a net operating loss of $2.875 million, and completed dosing in its Phase 2b OST-HER2 osteosarcoma trial, with topline data expected in December 2024. OST-HER2 has received Rare Pediatric Disease, Fast Track, and Orphan Drug designations from FDA and EMA.

OS Therapies appoints Avril McKean Dieser and Olivier R. Jarry to its Board of Directors, bringing over 50 years of biopharmaceutical experience. The company also accepts the resignations of Dr. Colin Goddard and Mr. Joacim Borg.

OS Therapies announced development of two novel ADC therapeutic candidates targeting Breast, Lung, and Gastric Cancer, and Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, leveraging proprietary SiLinker™ technology.